Quality of surgery and RT in stage IIIN2 NSCLC: Insights from the Lung Adjuvant Radiotherapy trial
Moukasse, Y. Pourel, N. Lerouge, D. Faivre-Finn, Corinne Ramella, S. Edwards, J. Van Schil, P. Rami-Porta, R. Thomas, P. Bardet, A
Moukasse, Y.
Pourel, N.
Lerouge, D.
Faivre-Finn, Corinne
Ramella, S.
Edwards, J.
Van Schil, P.
Rami-Porta, R.
Thomas, P.
Bardet, A
Citations
Altmetric:
Abstract
Purpose or Objective
The objective of the phase III Lung Adjuvant Radiotherapy
Trial (LungART) is to determine if modern conformal
mediastinal postoperative radiotherapy (PORT), adapted
to tumor location and involved lymph nodes (LN), can
improve disease-free survival (DFS) for completely
resected stage III N2 non-small-cell lung cancer
(NSCLC) patients (pts). Given the potential toxicity of
PORT in older randomized trials, it is crucial to investigate
the quality assurance (QA) of both surgery and
radiotherapy (RT).
Material and Methods
First, a surgical advisory committee composed of 4 expert
thoracic surgeons reviews anonymized surgical and
pathological reports, and establishes the quality of tumor
resection and nodal exploration, taking into consideration
the international guidelines. Then, for the RT QA analyses,
RT advisory committee composed of 4 expert
thoracic radiation oncologists, reassesses dosimetric plans
of each patient treated in the PORT arm and correlates
nodal target coverage with surgical data.
Results
In June 2019, from 252 patients treated in PORT arm, 142
files have already been analyzed for surgical and RT QA. Conclusion
Despite the encouraging survival rates, similar or even
better than those observed in the modern series of
conventionally fractionated RT-CHT, the observed rate of
toxic and probably toxic deaths that occurred within one
year after treatment challenges the safety of the routine
use of accelerated hypofractionated RT with concomitant full dose CHT.
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Moukasse Y, Pourel N, Lerouge D, Faivre-Finn C, Ramella S, Edwards J, et al. PH-0280: Quality of surgery and RT in stage IIIN2 NSCLC: Insights from the Lung Adjuvant Radiotherapy trial. Radiotherapy and Oncology . 2020 Nov;152:S140–1.